Longer progression-free survival compared to high-dose octreotide long-acting repeatable
THURSDAY, Jan. 12, 2017 (HealthDay News) — For patients with advanced midgut neuroendocrine tumors, lutetium-177 (177Lu)-Dotatate is associated with longer progression-free survival than high-dose octreotide long-acting repeatable (LAR), according to a study published in the Jan. 12 issue of the New England Journal of Medicine.
Jonathan Strosberg, M.D., from Moffitt Cancer Center in Tampa, Fla., and colleagues randomized 229 patients with well-differentiated, metastatic midgut neuroendocrine tumors to receive 177Lu-Dotatate (116 patients) at a dose of 7.4 GBq every eight weeks plus best supportive care, including octreotide LAR (30 mg administered intramuscularly), or octreotide LAR alone (60 mg administered intramuscularly) every four weeks (113 patients; control group).
The researchers found that the estimated rate of progression-free survival at month 20 was 65.2 and 10.8 percent in the 177Lu-Dotatate and control groups, respectively. The response rate was 18 and 3 percent in the 177Lu-Dotatate and control groups, respectively (P < 0.001). There were 14 and 26 deaths in the 177Lu-Dotatate and control groups, respectively, in the planned interim analysis of overall survival (P = 0.004). One, 2, and 9 percent of patients in the 177Lu-Dotatate group had grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia, respectively, compared with no patients in the control group.
“Treatment with 177Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors,” the authors write.
The study was funded by Advanced Accelerator Applications.
Full Text (subscription or payment may be required)
Copyright © 2017 HealthDay. All rights reserved.
